Browse grants

DARPA - Biological Technologies Office · Amount varies

The Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO) is soliciting proposals that leverage biological properties and processes to revolutionize our ability to protect the nation’s warfighters. Specifically excluded is research that primarily results in evolutionary improvements to the existing state of practice.

DOC NOAA - ERA Production · $0

This notice is not a mechanism to fund existing NOAA awards. The purpose of this notice is to request applications for special projects and programs associated with NOAA's strategic plan and mission goals, as well as to provide the general public with information and guidelines on how NOAA will select applications and administer discretionary Federal assistance under this Broad Agency Announcement (BAA). Each NOAA Line or Staff Office that supports financial assistance (National Marine Fisheries Service, National Ocean Service, National Weather Service, Office of Atmospheric Research, Office of Education, and National Environmental Satellite Data Information Service) has a separate BAA found in Grants.gov, so applicants should submit their application to the BAA for the Line Office that best fits their application. A description of NOAA Line Offices is found at https://www.corporateservices.noaa.gov/public/lineoffices.html and https://www.noaa.gov/office-education, and applicants may contact the Agency Contacts in Section VII. below for more information. If you submit the same application to more than Line Office, mention this in your application and notify the relevant contacts in Section VII. so that NOAA may coordinate internally.

Office of Science · $50K–$5M

The Office of Science (SC) of the Department of Energy (DOE) hereby announces its continuing interest in receiving applications for support of work in the following program areas: Advanced Scientific Computing Research, Basic Energy Sciences, Biological and Environmental Research, Fusion Energy Sciences, High Energy Physics, Nuclear Physics, and Isotope R&D and Production. On September 3, 1992, DOE published in the Federal Register the Office of Energy Research Financial Assistance Program (now called the Office of Science Financial Assistance Program), 10 CFR 605, as a Final Rule, which contained a solicitation for this program. Information about submission of applications, eligibility, limitations, evaluation and selection processes and other policies and procedures are specified in 10 CFR 605. This NOFO is our annual open solicitation that covers all research areas in SC and is open throughout the Fiscal Year. Any research within SC’s Congressionally authorized mission may be proposed under this NOFO. This NOFO will remain open until September 30, 2026, 11:59 PM Eastern Time, or until it is succeeded by another issuance, whichever occurs first. This NOFO succeeds DE-FOA-0003432, which was published September 30, 2024.

U.S. National Science Foundation · Amount varies

The Universe is the ultimate laboratory, and we can now probe it as never before through several powerful and diverse windows – electromagnetic waves, high-energy particles, and gravitational waves. Each of these windows provides a different view. Together they reveal a detailed picture of the Universe that will allow us to study matter, energy, and the cosmos in fundamentally new ways. The “Windows on the Universe” Multi-Messenger Astrophysics (WoU-MMA) program identifies three categories of messengers - electromagnetic waves, high-energy particles including neutrinos and cosmic rays, and gravitational waves. The goals of WoU-MMA are to build the capabilities and accelerate the synergy between observations and theory to realize integrated, multi-messenger astrophysical explorations of the Universe. The WoU-MMA program welcomes proposals in any area of research supported through the participating divisions that address at least one of the following criteria: Coordination: Activities to coordinate observations involving more than one messenger. Observations: Observations of astrophysical objects or phenomena that are potentially sources of more than one messenger. Interpretation: Theory, experiment, simulations and other activities to understand or interpret observations of astrophysical objects that are sources of more than onemessenger. Competitive proposals will accelerate the progress in multi-messenger astrophysics and advance the community activities that have been developed during the initial five-year period of the WoU-MMA program. These build on observational and analysis capabilities at the intersection of the explorations enabled by each of the three windows. Efforts to integrate research communities to develop full interoperability between the three windows, and to develop a skilled new workforce in this field, are also encouraged. Proposals should be submitted to the relevant programs listed below (see Related Programs). The WoU-MMA program is not intended to replace existing programs that make awards that involve experimental or theoretical efforts related to each of the three messengers. Rather, the WoU-MMA program is meant to fund awards that have significant components of multi-messenger astrophysics. Priority will be given to proposals for dedicated efforts that significantly advance the WoU-MMA goals. A proposal that is requesting consideration within the context of WoU-MMA should begin the title with the identifying acronym "WoU-MMA:". PIs should ask for consideration and review as a WoU-MMA proposal only if the proposal addresses at least one of the criteria listed above. Proposals marked for consideration by the WoU-MMA program that do not address at least one of these criteria will be reviewed solely within the participating program(s) to which they were submitted. Supplement requests to existing awards within a program that address one of the above criteria will also be considered.

Office of Naval Research · Amount varies

ONR, ONRG, and MCWL are interested in receiving proposals for Long-Range S&T Projects that offer potential for advancement and improvement of Navy and Marine Corps operations. Readers should note that this is an announcement to declare ONR, ONRG and MCWL’s broad role in competitive funding of meritorious research across a spectrum of science and engineering disciplines. All responsible sources from academia, industry and the research community worldwide may submit proposals under this BAA. All businesses, both small and large, are encouraged to submit proposals and compete for funding consideration.

Naval Research Laboratory · $0

Amendment 0006 The purpose of this amendment is to extend the due date for acceptance of White Papers. All other terms and conditions remain unchanged. -------------------------------------------------------------- Amendment 0005 The purpose of this amendment is to provide a searchable list of Summary Topics contained in Appendix 1. Expanded descriptions of each topic can be found in the full announcement pdf. APPENDIX 1 – RESEARCH DESCRIPTION - SUMMARY TOPICS II. Detailed information about the funding opportunity The Naval Research Laboratory (NRL) is the Navy's corporate laboratory. NRL conducts basic and applied research for the Navy in a variety of scientific and technical disciplines. The basic research program is driven by perceptions about future requirements of the Navy. The Navy's operational effectiveness depends on its ability to keep pace with rapidly developing technologies. NRL contributes to this requirement by conducting research in the following areas, organized into NRL'S three research directorates and Naval Center for Space Technology: Systems Directorate Code 5000 Materials Science and Component Technology Directorate Code 6000 Ocean and Atmospheric Science and Technology Directorate Code 7000 Naval Center for Space Technology Code 8000 A. SYSTEMS DIRECTORATE - CODE 5000 53-24-01 - HIGH FREQUENCY RADAR 53-24-01C - HIGH FREQUENCY RADAR (CLASSIFIED) 53-24-02 - LOW-COST WIDEBAND ANTENNA ARRAY TECHNOLOGIES 53-24-03 - ADVANCED COMPUTATIONAL ELECTROMAGNETICS 55-24-01 - INFORMATION AND DECISION SCIENCES 55-24-02 - MATHEMATICAL FOUNDATIONS OF HIGH ASSURANCE COMPUTING 55-24-03 - HIGH ASSURANCE ENGINEERING AND COMPUTING 55-24-04 - ADVANCED NAVAL NETWORK SOLUTIONS 55-24-05 - FEDERATED, DISTRIBUTED COMPUTING/NETWORK INFRASTRUCTURE 56-24-01 - OPTICAL SCIENCES R&D 57-24-01 - ELECTROMAGNETIC TECHNIQUES AND TECHNOLOGY RESEARCH AND DEVELOPMENT 57-24-02 ​ - SHIPBOARD ELECTRONIC WARFARE B. MATERIALS SCIENCE AND COMPONENT TECHNOLOGY DIRECTORATE CODE 6000 60-24-01 - HIGH PERFORMANCE COMPUTING ON MASSIVELY PARALLEL ARCHITECTURES 61-24-01 - ELECTROCHEMICAL ENERGY STORAGE, CONVERSION AND COMMAND/CONTROL 61-24-02 - CORROSION PROCESSES, CONTROL, MITIGATION, AND TECHNOLOGY 61-24-03 - APPLICATIONS OF MOLECULAR BIOLOGY, BIOCHEMISTRY, ANALYTICAL CHEMISTRY AND ADVANCED LASER TECHNIQUES 61-24-04 - MULTIECHELON DIAGNOSTICS (MEDx) TECHNOLOGY DEVELOPMENT AND TIERED EVALUATION 63-24-01 - MATERIALS PERFORMANCE, PROCESSING, AND MODELING 67-24-01 - BASIC AND APPLIED RESEARCH IN PLASMA SCIENCE 68-24-01 - RADIATION EFFECTS RESEARCH 68-24-02 - PHOTOVOLTAICS FOR PORTABLE POWER C. OCEAN AND ATMOSPHERIC SCIENCE AND TECHNOLOGY DIRECTORATE CODE 7000 71-24-01 - ACOUSTIC SIMULATION AND TACTICS 72-24-01 - LOW FREQUENCY RADIO INTERFEROMETRY 72-24-02 - OPTICAL REMOTE SENSING OF THE COASTAL REGIME 72-24-03 - REMOTE SENSORS AND IMAGING SYSTEMS 72-24-04 - AIRBORNE, SHIPBOARD, AND OVERHEAD DATA ACQUISITION AND ANALYSIS 73-24-01 - OCEAN DYNAMICS AND PREDICTION OCEANOGRAPHY 73-24-02 - SEAFLOOR SCIENCES 73-24-03 - GEOSPATIAL SCIENCES AND TECHNOLOGY 75-24-01 - ATMOSPHERIC EFFECTS, ANALYSIS, AND PREDICTION 76-24-01 - RESEARCH INTO SPACE, BACKGROUNDS, IMAGING AND MODELING D. NAVAL CENTER FOR SPACE TECHNOLOGY CODE 8000 82-24-01 - SPACECRAFT & SPACE SYSTEMS TECHNOLOGY -------------------------------------------------------------- Amendment 0004 The purpose of this amendment is to extend the due date for acceptance of White Papers and revise Appendix 1 Summary Topics and email addresses in it’s entirety. -------------------------------------------------------------- Amendment 0003 The purpose of this amendment is to extend the due date for acceptance of White Papers. All other terms and conditions remain unchanged. ------------------------------------------------------------- Amendment 0002 The purpose of this amendment is to extend the due date for acceptance of White Papers. All other terms and conditions remain unchanged. ------------------------------------------------------------- Amendment 0001 The purpose of this amendment is to extend the due date for acceptance of White Papers. All other terms and conditions remain unchanged. -------------------------------------------------------------- The Naval Research Laboratory is interested in receiving innovative proposals that offer potential for advancement and improvement in the technical topic areas listed. This notice constitutes a Broad Agency Announcement (BAA) as contemplated in FAR 6.302(d) that provides for the competitive selection of research proposals. The Government reserves the right to select for award all, some, or none of the proposals received. Awards under this BAA are expected to take the form of Contracts, Grants, Cooperative Agreements and Other Transactions may also be awarded if appropriate. NRL encourages Educational Institutions, Small Businesses (SBs), Small Disadvantaged Business Concerns (SDBs) and Historically Black Colleges and Universities (HBCUs) and Minority Institutions (MIs) to submit proposals under this BAA. In order to conserve valuable offeror and Government resources, prospective offerors shall first submit a White Paper (WP) to the email address identified in the individual Summary Topics contained in Appendix 1, to include a rough cost estimate. If there is interest in the proposed research the offeror will be invited to submit a Formal Proposal. The selection of proposals for award will be based on a scientific review of proposals submitted in response to each BAA Summary Topic. The major purpose of the evaluation will be to determine the relative merit of the technical approach of each proposal. Business and contractual aspects, including proposed cost and cost realism, will also be considered as part of the evaluation. Selection of proposals for award will be based on the potential benefits to the Government weighed against the cost of the proposals, in view of the availability of funds. The complete BAA including proposal preparation instructions, award considerations, and evaluation criteria is also available at https://www.nrl.navy.mil/Doing-Business/Contracts/Broad-Agency-Announcements/ .

Defense Health Agency Contracting Activity - DHACA · Amount varies

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of amyotrophic lateral sclerosis (ALS). Projects may range from phase 1 to small-scale phase 2 trials. Applications must address one of the following focus areas: · Biomarker-Driven Interventions: Disease-modifying interventions, with mechanism-specific biomarkers to predict which clinical trial participants are likely to respond, demonstrate target engagement, and effects on the intended biological pathway. · Clinical Care: Improving aspects of clinical care and symptom management for ALS. Distinctive Features: Funding from this award mechanism must support a clinical trial. The clinical trial should begin no later than 12 months after the award date or 18 months for U.S. Food and Drug Administration (FDA)-regulated studies. Projects proposing a therapeutic intervention (drug, biologic, and/or device) must incorporate biomarkers specific to the intervention into the trial design. All pre-applications and applications are required to incorporate community collaboration, as described in Section 3.2.2, to optimize research impact. Applications must include a detailed Regulatory Strategy plan that outlines the approach for obtaining regulatory approvals, if required, specifically for the funded portion of the study. In addition, applications must provide a separate Transition Plan that describes how the outcomes of the study will be advanced to the next phase of development, beyond the scope of the funded work.

Defense Health Agency Contracting Activity - DHACA · Amount varies

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Award supports collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer. Applications must propose a synergistic, highly integrated, multidisciplinary and multi-institutional consortium of leading scientists, clinicians and breast cancer consumer advocates that will address a major problem in a way that a single investigator or group could not accomplish. The consortium’s collaborative efforts must make a transformative impact in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. If the application addresses a different fundamental issue, the application must couple it with at least one of the overarching challenges. Distinctive Features: This funding mechanism allows for up to five Principal Investigators (PIs) which includes the Consortium Director and three or four Project Team PIs. Applications must include at least one breast cancer consumer advocate per project team. Only the Consortium Director will submit a pre-application, but all PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Consortium Director and Project Team PIs) applications by the full application deadline may result in administrative withdrawal.

Defense Health Agency Contracting Activity - DHACA · Amount varies

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at amyotrophic lateral sclerosis (ALS) drug or therapy discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation. Distinctive Features: Potential impact and innovation are important features of the TIA. Applications may demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. While the inclusion of preliminary data is not prohibited, the strength of the application should rely on the approach.

Defense Health Agency Contracting Activity - DHACA · Amount varies

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients. Distinctive Features: To meet the intent of the funding opportunity, applications may address clinical biomarkers and/or clinical outcomes . This may include the identification, development, and/or validation of promising biomarkers for ALS, which may include, but are not limited to susceptibility/risk, diagnostic, monitoring/disease progression, prognostic, predictive, response, or safety biomarkers. Clinical Outcomes projects may focus on the identification, development, and/or validation of clinician-, observer-, or patient-reported, and/or performance outcome measures for ALS. Projects may include the optimization of current outcome measures already in use. Applications may utilize digital health measures, including wearable devices, smart-phone sensors, video or voice recordings, imaging studies, or other devices which record disease-relevant physiological data and/or outcomes. Community Collaboration is an important element of the FY26 ALSRP COBA. Applicants will be expected to articulate how the proposed research question or study design was informed by the ALS lived experience community.

Defense Health Agency Contracting Activity - DHACA · Amount varies

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Applications must address the challenge in a way that can lead to a breakthrough and have major impact. The FY26 Breakthrough Award mechanism contains four different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level specifies a distinct research scope. This program announcement discusses the Breakthrough Award Level 3. Distinctive Features: · For this funding mechanism, small-scale clinical trials are allowed but not required. Applications proposing projects with a clinical trial should be submitted under the Clinical Trial option. · The research team must include two or more breast cancer consumer advocates. · This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.

Defense Health Agency Contracting Activity - DHACA · Amount varies

Summary: The fiscal year 2026 (FY26) Rare Cancers Research Program (RCRP) Concept Award (CA) supports highly innovative, untested, potentially groundbreaking novel concepts in rare cancers. Applications must describe how the new idea will be innovative and present as a novel course of investigation in the field of rare cancers. Distinctive Features: Preliminary data are not required. Due to the blinded nature of the review process, identifying or making references to the Principal Investigator (PI), collaborator(s), or their organization(s) in the proposal Project Narrative, Supporting Documentations, Impact Statement, Justification Statement, and Statement of Work (SOW) is prohibited and will result in administrative rejection of the application.

Defense Health Agency Contracting Activity - DHACA · Amount varies

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology. Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including whole-animal and cellular model systems. Distinctive Features: Mechanism-specific , predictive/cohort-selective, target engagement and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY26 ALSRP Therapeutic Development Award . If appropriate mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be apparent in the application. Development of biomarkers for the purposes of diagnosis, prognosis, or measurement of general disease progression without consideration of the therapeutic development process will not be supported. Therapeutic candidates which have already been granted an IND are not appropriate for this mechanism.

Defense Health Agency Contracting Activity - DHACA · Amount varies

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Applications must address the challenge in a way that can lead to a breakthrough and have major impact. The FY26 Breakthrough Award mechanism contains four different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level specifies a distinct research scope. This program announcement discusses the Breakthrough Award Level 4. Distinctive Features: · Clinical trials are required. · The research team must include two or more breast cancer consumer advocates. · This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.

U.S. National Science Foundation · $475K–$7.5M

With a focus on two-year Institutions of Higher Education (IHEs), the Advanced Technological Education (ATE) program supports the education of technicians for the high-technology fields that drive our nation's economy. The program involves partnerships between academic institutions (grades 7-12, IHEs), industry, and economic development agencies to promote improvement in the education of science and engineering technicians. It is strongly recommended that projects be faculty-led and required that courses and programs are credit-bearing, although materials developed may also be used for incumbent worker education. Materials may also be adapted and implemented as credit-bearing courses. The ATE program supports curriculum development; professional development of college faculty and secondary school teachers; career pathway development for both students and incumbent workers; and other activities including applied research projects that advance the knowledge base related to technician education. The ATE program encourages partnerships with other entities that may impact technician education. For example, with the National Institute of Standards and Technology (NIST) Manufacturing Extension Partnerships (MEPs) ( http://www.nist.gov/mep/index.cfm ) as applicable to support technician education programs and the industries they serve; and Manufacturing USA Institutes( https://manufacturing.gov/ ) addressing workforce development issues. The ATE program encourages proposals from Minority Serving Institutions as well as other institutions that support the recruitment, retention, and completion (certificate, degree, program)of the full spectrum of diverse talent that society has to offer, which includes underrepresented and underserved communities, in STEM technician education programs that award associate degrees.

U.S. National Science Foundation · $500K–$2.5M

The EDU Core Research (ECR) program offers this ECR:Core solicitation and invites proposals for fundamental research (curiosity-driven basic research and use-inspired basic research) that contributes to the general, explanatory knowledge that underlies STEM education in one or more of the three broadly conceived Research Areas: Research onSTEM Learning and Learning Environments, Research on Broadening Participation in STEM fields, andResearch on STEM Workforce Development. Within this framework, the ECR program supports a wide range of fundamental STEM education research activities, aimed at learners of all groups and ages in formal and informal settings. Fundamental researchgenerates knowledge and understanding with the potential for broad relevance. The potential implications of ECR fundamental research for improving STEM education practice may be indirect and long-term rather than direct and immediate. Moreover, whether they include basic or use-inspired basic research, all successful ECR:Core proposals focus on the advancement or refinement of foundational knowledge for STEM education. The amount of funding and duration requested in proposals submitted to the ECR:Core solicitation should align with the maturity of the proposed work and the size and scope of the empirical effort. The solicitation has three levels of funding with a range of budget sizes, and proposals may request a duration of 3 to 5 years for any level: (1)Level I proposals may request up to $500,000; (2)Level II proposals may request up to $1,500,000; (3)Level III proposalsmay request up to $2,500,000. All proposals should justify the level of funding and duration in the project description.

Defense Health Agency Contracting Activity - DHACA · Amount varies

Summary: The OCRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ovarian cancer. Distinctive Features: Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.

Defense Health Agency Contracting Activity - DHACA · Amount varies

Summary: The Ovarian Cancer Pilot Award supports research that expands or modifies current thinking about and/or approaches in ovarian cancer, exploring innovative concepts or theories in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward. Distinctive Features: Innovation is key. Research projects that demonstrate exceptional scientific merit but lack innovation do not meet the intent of the mechanism. Preliminary data are not required but are allowed for this mechanism. This mechanism includes a blinded pre-application component. Pre-applications to this funding opportunity will undergo a blinded pre-application screening. While preparing your pre-application, do not include any material that may identify the PI, a collaborator, or the organization of the PI or collaborator.

Defense Health Agency Contracting Activity - DHACA · Amount varies

Summary: Initially created in FY09, the OCRP Ovarian Cancer Academy (OCA) is a unique, interactive virtual academy providing intensive mentoring, national networking, collaborations, and a peer group for junior faculty. The overarching goal of the OCA is to conduct innovative and impactful ovarian cancer research while developing successful, highly productive ovarian cancer researchers in a collaborative research and career development environment. Distinctive Features: The OCA is a virtual career development and research training platform that consists of Early-Career Investigators (ECIs), their Designated Mentors, and an Academy Dean and Assistant Dean. The OCA-ECI Award is not a traditional career development award; the ECI is expected to participate in monthly webinars and annual workshops and to communicate and collaborate with other members of the Academy (other ECIs, Mentors, the Dean and Assistant Dean) as well as with the advocacy community.

Defense Health Agency Contracting Activity - DHACA · Amount varies

Summary: Created in FY23, the Ovarian Cancer Clinical Trial Academy (OCCTA) supports the next generation of Early-Career Investigators (ECIs) in clinical trial research to produce effective treatments and cures for ovarian cancer. The OCCTA, through its Leadership, provides for professional and leadership development of the ECIs to include skills and competencies needed to execute clinical trials, providing intensive mentoring, national networking, collaborations, and a peer group for junior clinical trialists. The OCCTA will bring together established investigators (the Academy Dean and Assistant Dean), established Career Guides (mentors), and a group of ECIs/Scholars to conduct successful, highly productive clinical trials in ovarian cancer. Distinctive Features: Research funded under this FY26 funding opportunity will support translational research and small-scale, early-phase clinical trials in ovarian cancer. Preliminary data are required, however, these data do not necessarily need to be derived from the ovarian cancer research field. The ECI must be within 12 years of their last postdoctoral research position (Ph.D.), clinical fellowship (M.D.), or equivalent at the time of full application submission deadline. The ECI must commit no less than 25% effort to this award and/or OCCTA activities for the first two years. The Designated Mentor must be a clinical trialist with a strong record of mentoring and training early-career investigators.